Leerink Partnrs Research Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)Zolmax • about 1 month ago
Allakos Inc. (NASDAQ:ALLK Free Report) Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Allakos in a research report issued to clients and...
Share to Feed
Allakos Inc. (NASDAQ:ALLK Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...
Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development FocusRelated Stocks: ALLK...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company ) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Investors eyeing a purchase of Allakos Inc (ALLK) shares, but cautious about paying the going market price of 1.48/share, might benefit from considering selling puts among the alternative...
Shares of Allakos Inc. (NASDAQ:ALLK Get Free Report) have earned an average rating of Hold from the seven analysts that are currently covering the company, MarketBeat Ratings...
Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages AK006 inhibited mast cell activation and reduced mast cell numbers...
Data provide insights on the signaling pathways involved with AK006 mast cell inhibition AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells SAN...